These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7588991)

  • 1. BIO-international '94 Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies and Pre-Conference Satellite on 'In Vivo/In Vitro Correlation'. Munich, Germany, June 14-17, 1994.
    Blume HH; McGilveray IJ; Midha KK
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):3-13. PubMed ID: 7588991
    [No Abstract]   [Full Text] [Related]  

  • 2. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies.
    Blume HH; Midha KK
    J Pharm Sci; 1993 Nov; 82(11):1186-9. PubMed ID: 7904641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.
    Shah VP; Midha KK; Dighe S; McGilveray IJ; Skelly JP; Yacobi A; Layloff T; Viswanathan CT; Cook CE; McDowall RD
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):249-55. PubMed ID: 1823867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of the 4-6-20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies.
    Kringle RO
    Pharm Res; 1994 Apr; 11(4):556-60. PubMed ID: 8058615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability/bioequivalence of modified release drug delivery systems: which pharmacokinetic parameters to determine, single or multiple dose studies, pretests, conditions and other aspects.
    Ritschel WA
    Methods Find Exp Clin Pharmacol; 1992; 14(6):469-82. PubMed ID: 1469957
    [No Abstract]   [Full Text] [Related]  

  • 8. When are bioavailability studies required? A German proposal.
    Gleiter CH; Klotz U; Kuhlmann J; Blume H; Stanislaus F; Harder S; Paulus H; Poethko-Müller C; Holz-Slomczyk M
    J Clin Pharmacol; 1998 Oct; 38(10):904-11. PubMed ID: 9807970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conference report: Bio-International 2005.
    Midha KK; Shah VP; Singh GJ; Patnaik R
    J Pharm Sci; 2007 Apr; 96(4):747-54. PubMed ID: 17094144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptable and unacceptable procedures in bioavailability and bioequivalence trials.
    Marzo A; Ceppi Monti N
    Pharmacol Res; 1998 Nov; 38(5):401-4. PubMed ID: 9806821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [3rd International Regulatory Workshop on A to Z on bioequivalence, bioanalysis, dissolution and biosimilarity].
    Acta Pharm Hung; 2012; 82(3):121-4. PubMed ID: 23230651
    [No Abstract]   [Full Text] [Related]  

  • 12. [Assessment of bioequivalence].
    Aoyagi N
    Eisei Shikenjo Hokoku; 1996; (114):141-2. PubMed ID: 9037886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relative bioavailability and bioequivalence of the antimycotics ketoconazole and fluconazole].
    Ptitsina SN; Bobrov VI; Borisov MM
    Antibiot Khimioter; 2006; 51(11-12):24-8. PubMed ID: 18318144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and bioequivalence: focus on physiological factors and variability.
    Karalis V; Macheras P; Van Peer A; Shah VP
    Pharm Res; 2008 Aug; 25(8):1956-62. PubMed ID: 18551249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japanese guidance on bioavailability and bioequivalence.
    Aoyagi N
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):28-31. PubMed ID: 11032086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Different Sampling Schedules on Results of Bioavailability and Bioequivalence Studies: Evaluation by Means of Monte Carlo Simulations.
    Kano EK; Chiann C; Fukuda K; Porta V
    Drug Res (Stuttg); 2017 Aug; 67(8):451-457. PubMed ID: 28561232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Product Selection--Part 2: Scientific basis of bioavailability and bioequivalence testing.
    Meyer MC
    Am Pharm; 1991 Aug; NS31(8):47-52. PubMed ID: 1927900
    [No Abstract]   [Full Text] [Related]  

  • 18. Half-life revisited: implication in clinical trials and bioavailability/bioequivalence evaluation.
    Chen ML; Pelsor FR
    J Pharm Sci; 1991 Apr; 80(4):406-8. PubMed ID: 1865346
    [No Abstract]   [Full Text] [Related]  

  • 19. Consensus report from "Bio International '89": issues in the evaluation of bioavailability data.
    McGilveray IJ; Midha KK; Skelly JP; Dighe S; Doluisio JT; French IW; Karim A; Burford R
    J Pharm Sci; 1990 Oct; 79(10):945-6. PubMed ID: 2280368
    [No Abstract]   [Full Text] [Related]  

  • 20. Alternative approach to relative bioavailability and bioequivalence evaluation, with drugs following Michaelis-Menten elimination kinetics.
    Fagiolino P; Stareczek S
    Farmaco; 1990 Sep; 45(9):1027-36. PubMed ID: 2282123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.